Navigation Links
Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
Date:6/2/2008

OSAKA, Japan and UNION CITY, Calif., June 2 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. and MacuSight, Inc. today announced that the two companies have entered into a research and development collaboration and license agreement for the Japanese and Asian development and commercialization of sirolimus for the treatment of ocular diseases and conditions including wet age related macular degeneration (wet AMD) and diabetic macular edema (DME). Sirolimus, originally known as rapamycin, is a highly-potent, broad-acting compound that has demonstrated the ability to combat a broad range of diseases and conditions. MacuSight is presently initiating a Phase 2 clinical trial of sirolimus in DME and preparing to initiate a Phase 2 study in wet AMD in the second half of 2008.

Under terms of the agreement, Santen receives rights to develop and commercialize sirolimus for ocular diseases and conditions in Japan and Asia. MacuSight retains development and commercialization rights to sirolimus in all other markets. While specific financial details of the agreement have not been disclosed, Santen has agreed to provide MacuSight with an initial upfront payment of $50 million dollars for funding MacuSight's continuing research and development efforts, as well as clinical development of sirolimus. Additionally, Santen will provide MacuSight with milestone payments and a royalty on future sirolimus sales in the Japanese and Asian markets.

"We believe that this deal represents tremendous validation for our sirolimus development program and signals a critical corporate milestone in the history of MacuSight," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "We are thrilled to be able to partner this program with a company of Santen's experience, particularly as it relates to developing and commercializing pharmaceuticals in Japan and Asia. We look forward to a long and productive relationship with our new collaborators."

Sir
'/>"/>

SOURCE MacuSight, Inc.; Santen Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. GeneNews announces management changes to support commercialization of ColonSentry(TM)
3. AMDL Announces New GOODNAK Consumer Anti-Aging Products for Use in Skin Renewal Treatments
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
6. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
7. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
8. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
9. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
10. Favrille Announces Workforce Reduction
11. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... IN (PRWEB) July 25, 2014 At ... (FAA) has granted a 60-day extension for the public ... the Special Rule for Model Aircraft established by Congress ... of 2012. The 60-day extension establishes the new deadline ... United States Department of Transportation/FAA notice published in the ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... , , SAN DIEGO, July ... finalization of the protocol for the Company,s Phase II trial of ANA598 ... Allowance of the protocol has been received from the United States Food ... the next several weeks. , , In the Phase ...
... ... efficiency, renewable energy and reforestation projects , ... Falmouth, ME (PRWEB) July 30, 2009 -- IntertechPira has teamed ... associated with the 2009 Biopolymers Symposium and is offsetting those emissions to make the ...
... , , RALEIGH, N.C. , ... for the management and analysis of genetic data, today announced that ... Hospital will utilize SmartGene,s advanced technology and integrated Web-based services to ... by sequence analysis. , , Some bacteria and ...
Cached Biology Technology:Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5Biopolymers Symposium 2009 Teams with Carbonfund.org to Create a Zero-Carbon Event 2SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2
(Date:7/27/2014)... might have survived the asteroid strike that wiped them ... later in history, scientists say. , A fresh study ... helped palaeontologists to build a new narrative of the ... They found that in the few million years before ... was experiencing environmental upheaval. This included extensive volcanic activity, ...
(Date:7/27/2014)... climate change to cut food supplies. But these studies ... increasing temperature and air pollution specifically ozone pollution, ... study involving researchers at MIT shows that these interactions ... take both warming and air pollution into account in ... at global production of four leading food crops ...
(Date:7/25/2014)... In the first broad-scale estimate of air pollution removal ... calculated that trees are saving more than 850 human ... respiratory symptoms. , While trees, pollution removal equated to ... percent, the impacts of that improvement are substantial. Researchers ... pollution at nearly $7 billion every year in a ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3First national study finds trees saving lives, reducing respiratory problems 2
... up efforts to cut waste, reduce energy use and ... the number of planet-friendly standards and regulations also is ... of options for "going green." National Institute of Standards ... help organizations of all types sort through the welter ...
... Exotic bacteria that do not rely on oxygen may have ... early atmosphere, according to a theory that UChicago researcher Albert ... volcanic crater in Siberia. He has found that bacteria ... a surprising twist that scientists must take into account as ...
... American Chemical Society (ACS) today released a new episode ... podcast series showcasing a discovery that could mean greener ... used to make everything from paint to diapers. ... new way to make acrylic acid, a key industrial ...
Cached Biology News:NIST prototypes framework for evaluating sustainability standards 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
... HVJ (hemagglutinating virus of Japan, also ... a tool for transfection of molecules by ... are for siRNA (RNAi), Protein, Oligo, cDNA, ... and in vivo. GenomONE-Neo EX has a ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
... to help promote genomics-based research with S. aureus, ... that contains PCR primers to amplify all open ... addition, primer pairs are included to amplify ORFs ... N315 strains of S. aureus. The ORFmer set ...
Biology Products: